Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma

Journal of Gastrointestinal Oncology

Volumn 6, Issue 5, 2015, Pages 469-478

  Bhangoo, Munveer Singh ^a   Karnani, Diraj R ^a   Hein, Paul N ^b   Giap, Huan ^c   Knowles, Harry ^a   Issa, Chris ^c   Steuterman, Steve ^d   Pockros, Paul ^a   Frenette, Catherine ^a  

^a SCRIPPS GREEN HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Scripps Proton Therapy Center   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

radioembolization; SIR spheres; Therasphere; Unresectable hepatocellular carcinoma (HCC); Yttrium 90 (Y 90) microspheres

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SORAFENIB; YTTRIUM 90;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HUMAN; LIVER CELL CARCINOMA; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PULMONARY SHUNT; RADIATION DOSE; RADIATION SAFETY; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; STOMACH ULCER; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84995802705     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2015.056     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
3. McDermott WV, Cady B, Georgi B, et al. Primary cancer of the liver. Evaluation, treatment, and prognosis. Arch Surg 1989;124:552-4; discussion 554-5.
4. Johnson PJ. Why can't we cure primary liver cancer? Eur J Cancer 1995;31A: 1562-4.
5. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.
6. Bruix J, Sherman M Practice Guidelines Committee, et al. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
8. Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-8.
9. Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006;23:64-72.
10. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205-13.
11. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637-44.
12. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-81.
13. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4.
14. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
15. SIR-Spheres User's Manual. Sirtex Medical Limited. 2004;202:38-42. Available online: http://www.westernesse. com/portfoliolks/projects/sirtex/site/pdfs/sir-spheres_user_manual.pdf.
16. SIR-Spheres Package Insert. Sirtex Medical Limited, 2004. Available online: http://www.sirtex.com/media/29845/ssl-us-10.pdf.
17. TheraSphere Package Insert. MDS Nordion, 2004. Available online: http://www.therasphere.com/physicians-package-insert/package-insert-eu-en.pdf.
18. Kennedy A, Coldwell D, Sangro B, et al. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 2012;35:91-9.
19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
20. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-81.
21. Fox RA, Klemp PF, Egan G, et al. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:463-7.
22. Ackerman NB, Lien WM, Kondi ES, et al. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumors. Surgery 1969;66:1067-72.
23. Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg 1989;76:545-8.
24. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552-63.
25. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009;19:951-9.
26. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60.
27. Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28:81-99.
28. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007;188:768-75.
29. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792-800.
30. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-81.
31. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583-92.
32. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16:1627-39.
33. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37.
34. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005;25:S41-55.
35. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29:522-9.
36. Murthy R, Kamat P, Nuñez R, et al. Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Intervent Radiol 2008;25:48-57.
37. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-14.
38. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:224-30.
39. Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358-65.e1.
40. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
41. Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010;21:1377-84.
42. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int 2015;35:1036-47.
43. Gadani S, Mahvash A, Avritscher R, et al. Yttirum-90 resin microspheres as an adjunct to sorafenib in patients with unresectable HCC: a retrospective study for evaluation of survival benefit and adverse events. JVIR 2013;24:S35.